In washed human platelets, morin hydrate inhibited collagen-induced aggregation with a reported approximate IC50 of 40 μM. Aggregation triggered by thrombin, U46619 or arachidonic acid was not inhibited at the tested 20–80 μM concentrations. This response is specific to the tested agonist conditions. [2]
Suppression of human IAPP aggregation with orthogonal assay validation
Biochemical assay · Cell-free synthetic human islet amyloid polypeptide (IAPP), 32 μM [1]
Morin hydrate reduced fibrillar material in TEM concentration comparisons and suppressed the rise in right-angle light scattering at fivefold molar excess. Residual thin or short structures and amorphous material remained visible; the evidence supports inhibition of fibril formation under these conditions, not complete removal of all aggregates. Myricetin retained fibrils despite low thioflavin-T fluorescence, demonstrating a false-positive risk for fluorescence-only screens.
Literature-Reported Treatment Conditions
- Treatment concentration
- Morin hydrate 32–320 μM with 32 μM IAPP (1:1 to 1:10); light-scattering validation used 160 μM morin hydrate (fivefold excess).
- Exposure duration
- TEM concentration series: 48 h; light scattering with TEM sampling at 42 h.
- Method
- Co-incubation from time zero at 25°C in 20 mM Tris-HCl, pH 7.4.
- Vehicle
- 0.25% DMSO (v/v).
- Reported limits
- No IC50 was established. TEM sampling is qualitative; light-scattering caption reports three separate measurements per sample, without establishing three independently prepared biological samples.
Methods and source locations
Compound reported in the paper: Morin hydrate; Compound label in the paper: Morin hydrate
Reported effects of morin hydrate in this experimental model; no validation of an Adooq lot or conversion to anhydrous morin.
Results, inhibition and assay-interference subsections; Figures 2, 4, 5; Materials and Methods
Fibrillar morphology compared with IAPP alone: TEM at 48 h; same IAPP concentration and reported solvent across conditions. — Results, inhibition subsection; Figure 4A–E and caption
Aggregation signal with orthogonal morphology check: 500 nm; three separate measurements per sample; error bars are SD at each point; TEM sampled at 42 h. Sparse residual structures are visible in Figure 5C. — Results; Figure 5A–D and caption; Right-angle light scattering method
Myricetin comparator reveals thioflavin-T assay interference: Thioflavin-T kinetics and end-point TEM, IAPP with or without equimolar myricetin. — Results, Hydroxyflavones can interfere; Figure 2A–C and caption
Morphological disruption of preformed IAPP fibers
Biochemical assay · Cell-free preformed human IAPP amyloid, 32 μM IAPP [1]
After morin hydrate was added to preformed fibers, sampled TEM fields at 1–6 h showed loss of the dense long-fiber networks present immediately before addition, with residual nonfibrillar material. Thioflavin-T was used to establish that fibers had reached the plateau before treatment, not to quantify disassembly kinetics.
Literature-Reported Treatment Conditions
- Treatment concentration
- 160 μM morin hydrate added to 32 μM IAPP (fivefold excess).
- Exposure duration
- Added approximately 45 h after initiation of fiber formation; TEM at 1, 2, 4 and 6 h after addition.
- Method
- Addition to preformed fibers at 25°C, 20 mM Tris-HCl, pH 7.4.
- Vehicle
- 0.5% DMSO (v/v), as specified in Figure 6 caption.
- Reported limits
- Figure 6 provides a before-addition comparison but no time-matched vehicle-only post-addition TEM series. No quantitative disaggregation rate, IC50 or cellular protection endpoint.
Methods and source locations
Compound reported in the paper: Morin hydrate; Compound label in the paper: Morin hydrate
Reported effects of morin hydrate in this experimental model; no validation of an Adooq lot or conversion to anhydrous morin.
Results, disaggregation subsection; Figure 6; Amyloid disaggregation experiments method
Morphology of preformed fibers after compound addition: TEM; 100 nm scale bars; visual result does not establish soluble monomer recovery or biological safety. — Results, Morin hydrate disaggregates IAPP amyloid fibers; Figure 6B–F and caption
Agonist-dependent inhibition of washed human platelet aggregation
Cell-based study · Washed platelets from adult human volunteers; 3.6 × 10^8 cells/mL [2]
Morin hydrate inhibited collagen-stimulated aggregation with a reported approximate IC50 of 40 μM. At the tested concentrations, aggregation induced by thrombin, U46619 or arachidonic acid was not inhibited. These are ex vivo human platelet observations, not a clinical trial or an animal experiment.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20, 50 and 80 μM morin hydrate.
- Exposure duration
- 3 min preincubation; aggregation evaluated after 6 min reaction.
- Method
- Lumi-aggregometry; collagen 1 μg/mL, thrombin 0.01 U/mL, U46619 1 μM or arachidonic acid 60 μM.
- Vehicle
- Isovolumetric 0.1% DMSO control.
- Reported limits
- Figure 1 reports n = 4 and means ± SEM; whether n denotes independent donors is not specified in the reviewed text. IC50 is approximate, reported in Results rather than calculated here.
Methods and source locations
Compound reported in the paper: Morin hydrate; Compound label in the paper: MH
Reported effects of morin hydrate in this experimental model; no validation of an Adooq lot or conversion to anhydrous morin.
Results 2.1; Figure 1A–C; Methods 4.1–4.2
Collagen-induced washed human platelet aggregation: Light-transmission aggregation relative to individual untreated control; collagen 1 μg/mL; n = 4, means ± SEM for Figure 1. — Results 2.1; Figure 1B,C; Methods 4.2
Aggregation induced by thrombin, U46619 and arachidonic acid: Same aggregation comparison with solvent controls; thrombin 0.01 U/mL, U46619 1 μM and arachidonic acid 60 μM. — Results 2.1; Figure 1B,C and caption